MP Advisors Market Research Reports





RSS Sort By :
TITLE Price Buy Now More options

Domestic sales improved in 2014, recovering from the slump in the 2013 caused by the market's reaction to the new drug pricing policy. In 2015, growth is expected to continue to be healthy, as the momentum continues and improving economic grow...

$ 2000


The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strate...

$ 2000


With the recent development, Sri Lanka's aim of developing a pharma industry should be to penetrate the global market since the internal market is not sufficient for any big firm to operate at optimum levels. According to a report published by...

$ 2000


Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition.In the recent years several new therapies have been approved i...

$ 2000


All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche in...

$ 2000


The launch of Remicade biosimilar in Dec-2014 in the Japan pharma market demonstrated its changing regulatory environment; it is faster than U.S. in adapting to biosimilar use. After nine years of continuous efforts by the JP government to promote...

$ 4000


While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of importa...

$ 3000


Increasing rate of chronic diseases has emphasized the need of Prevention over Intervention. These proactive health solutions include nutritional supplements which promise medical or health benefits and fall between the food and pharma chain...

$ 2000


Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets , approaches and biology is discovered. One field which is poised to bring a paradigm change in the way diseases are treated in the next decades is t...

$ 2000


Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined. Current analgesics for persistent pain are relatively ineffective, are associated with significant adverse effects or abuse liabili...

$ 3000


Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients’ pain, function, and quality of life. Approved biologics fill in a critical unmet need...

$ 2500


There are more than 1400 sustained or controlled release drugs have been approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contri...

$ 2500


Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomod...

$ 2500


With three products and eight players already in market – Japan biosimilar market will enter new phase of biosimilars with first ‘mab’ approval expected in 2014. This approval (Remicade- FY03/13A sales ¥73.5, infiximab ...

$ 2500


XTANDI (Enzalutamide) – Does it have potential to compete against ARN-509 in earlier setting?Zytiga (Abiraterone Acetate) – Ongoing Combination trials creates potential beyond Patent Expiry<...

$ 2500


Novel approaches to treat infection is growing as the need is urgent! Misuse/overuse of antibiotics accelerated antimicrobial resistance (AMR) and has resulted in the emergence of super bugs” which are posing life threatening challeng...

$ 1500


Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology is discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing ...

$ 3000


Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvement in the length and quality of life and reduced disease burden for individuals and society. However, the need for innovative th...

$ 2500


Indian companies are taking center stage in Complex Generics at US and EU markets. In Bio-similars, Indian companies will have perhaps the largest basket aimed at Emerging Countries in 2014-16 and later for Developed countries. Though few bu...

$ 2500


2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations. We find these regulations to be 'decisive' in spurring ...

$ 2500

Live Chat Support
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441
Subscription Option

Use our subscription option and keep yourself updated about the latest from MP Advisors. We have market research reports of all sectors covered by the MP Advisors; you can access and utilize them at economical budgets.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100